Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Meta Expands AI Training With Employee Activity Tracking Tools 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
NEW YORK, March 20, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Middle District of North Carolina on behalf of investors who purchased Argos Therapeutics, Inc. ("Argos") (NASDAQ:ARGS) securities between February 7, 2014 and February 21, 2017.
Click here to learn about the case: http://www.wongesq.com/pslra/argos-therapeutics-inc. There is no cost or obligation to you.
According to the complaint, Argos issued materially false and/or misleading statements, causing the stock to trade at artificially inflated prices; following the release of adverse information, shares of Argos plummeted, damaging investors. In particular, the complaint alleges that Argos issued materially false and/or misleading information regarding the success and potential of its drug candidate AGS-003 (rocapuldencel-T).
On February 22, 2017, despite positive statements made by the Company, Argos then announced that the ADAPT study would be discontinued for futility. Following this news, shares of Argos fell approximately 66% to close at $1.48 per share on February 22, 2017.
If you suffered a loss in Argos you have until May 15, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/argos-therapeutics-inc.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
